Nakano K, et al. - From December 2012 to December 2016, 201 individuals who received cetuximab (an anti-epidermal growth factor receptor [EGFR] monoclonal antibody) for head and neck squamous cancer (HNSCC) were assessed by investigators for the incidence and risk factors related to interstitial lung disease (ILD), a known severe adverse event correlated with EGFR-targeted therapy. They recorded ILD in 9 candidates (4.5%) and among them, 8 were had grade 3 or higher disease. They noted high Krebs von den Lungen-6 (KL-6) and ≥50 pack-years of smoking were significantly predictive of correlated ILD.